enkephalin--leucine-2-alanine has been researched along with Stroke* in 2 studies
1 review(s) available for enkephalin--leucine-2-alanine and Stroke
Article | Year |
---|---|
Delta Opioid Receptor and Peptide: A Dynamic Therapy for Stroke and Other Neurological Disorders.
Research of the opioid system and its composite receptors and ligands has revealed its promise as a potential therapy for neurodegenerative diseases such as stroke and Parkinson's Disease. In particular, delta opioid receptors (DORs) have been elucidated as a therapeutically distinguished subset of opioid receptors and a compelling target for novel intervention techniques. Research is progressively shedding light on the underlying mechanism of DORs and has revealed two mechanisms of DOR neuroprotection; DORs function to maintain ionic homeostasis and also to trigger endogenous neuroprotective pathways. Delta opioid agonists such as (D-Ala2, D-Leu5) enkephalin (DADLE) have been shown to promote neuronal survival and decrease apoptosis, resulting in a substantial amount of research for its application as a neurological therapeutic. Most notably, DADLE has demonstrated significant potential to reduce cell death following ischemic events. Current research is working to reveal the complex mechanisms of DADLE's neuroprotective properties. Ultimately, our knowledge of the DOR receptors and agonists has made the opioid system a promising target for therapeutic intervention in many neurological disorders. Topics: Animals; Enkephalin, Leucine-2-Alanine; Humans; Nervous System Diseases; Opioid Peptides; Receptors, Opioid, delta; Stroke | 2018 |
1 other study(ies) available for enkephalin--leucine-2-alanine and Stroke
Article | Year |
---|---|
Delta opioid receptor and its peptide: a receptor-ligand neuroprotection.
In pursuit of neurological therapies, the opioid system, specifically delta opioid receptors and delta opioid peptides, demonstrates promising therapeutic potential for stroke, Parkinson's disease, and other degenerative neurological conditions. Recent studies offer strong evidence in support of the therapeutic use of delta opioid receptors, and provide insights into the underlying mechanisms of action. Delta opioid receptors have been shown to confer protective effects by mediating ionic homeostasis and activating endogenous neuroprotective pathways. Additionally, delta opioid agonists such as (D-Ala 2, D-Leu 5) enkephalin (DADLE) have been shown to decrease apoptosis and promote neuronal survival. In its entirety, the delta opioid system represents a promising target for neural therapies. Topics: Animals; Enkephalin, Leucine-2-Alanine; Humans; Neuroprotective Agents; Receptors, Opioid, delta; Stroke | 2013 |